November 6, 2017

Ensysce Biosciences Inc. to Present at Human Abuse Liability & Abuse-Deterrent Formulations Conference in Bethesda, Maryland on November 6th and 7th

Event Focuses on Creating and Marketing Drugs with Lowered Abuse Potential

SAN DIEGO--(BUSINESS WIRE)-- Ensysce Biosciences Inc., an integrated drug delivery company for both small and large molecules, today announced that it will be participating at ExL's 4th annual Human Abuse Liability & Abuse-Deterrent Formulations conference taking place at the Hyatt Regency in Bethesda, MD on November 6 and 7, 2017.

Opioid addiction has become a national crisis, and is leading to an increase in political and market pressure on drug companies from regulators, legislators, insurers, physicians, and patient advocacy groups. The conference is the largest industry event specifically focused on the full spectrum of challenges faced and strategies required to create and market drugs with lowered abuse potential. The conference will provide information and training to participants on topics such as: preclinical development of abuse-deterrent drugs and delivery mechanisms, clinical trial design, and building strong, reliable networks with every stakeholder throughout the regulatory and market access community.

Ensysce has been instrumental in designing and developing highly novel opioid prodrug products that are unique in the industry. Their BIO-MD™ abuse deterrent prodrugs are only effective if taken orally and activated through a two-step enzymatic process. The technology removes abuse by nasal or intravenous routes, and will not activate if chewed. Additionally, Ensysce has addressed the problem of overdose abuse with its MPAR™ (Multi-Pill Abuse Resistance) Overdose Protection Technology that combines BIO-MD™ products with inhibitors that prevent activation when larger than prescribed doses are ingested. PF614 and PF329, two new candidates for Multi-Pill Abuse Resistant formulations, have completed early clinical trials. Multiple protocols for later stages of development are being reviewed by the FDA and implementation of these are planned over the next year. Regulatory decisions will influence the further development of oral overdose preventive technologies.

Ensysce's Chief Medical Officer, Dr. William K. Schmidt, will be presenting the topic "Advancing the Technical and Clinical Development of Oral Overdose Preventative Formulations" at 1:30pm on November 7th.

"Dr. Schmidt will be introducing our delivery platforms and sharing our development strategies," said Dr. Lynn Kirkpatrick, Ensysce Biosciences Inc. Chief Executive Officer. "It's very appropriate that this discussion takes place at this conference, as this is the premier event for the key stakeholders in our industry."

About Ensysce Biosciences:

Ensysce Biosciences, San Diego CA, is an integrated drug delivery company for both small and large molecules. The BIO-MD™ prodrug abuse deterrent and MPAR™ overdose resistant pain platforms of Ensysce eliminate the ability to abuse opioid products by the non-oral route, something that is the fastest growing drug problem in the US and that leads to billions in healthcare costs annually. The technology, with a worldwide intellectual patent protection, has been successfully validated in Phase 1 studies of the BIO-MD™ hydromorphone prodrug, PF329 and oxycodone prodrug, PF614. Ensysce has an extensive worldwide intellectual property portfolio, including technology developed at Rice University by Nobel Laurate, Dr. Richard Smalley, for the use of SWCNT for therapeutic applications, and a portfolio covering a wide array of prescription drug prodrug compositions to overcome the abuse, especially for the highly abused opioid products. **www.ensysce.com**

View source version on businesswire.com:
http://www.businesswire.com/news/home/20171106005064/en/

Ensysce Biosciences Inc.
Dr. Lynn Kirkpatrick, 858-242-1553
CEO
lkirkpatrick@ensysce.com
www.ensysce.com

Source: Ensysce Biosciences Inc.